Jan Lebl

Jan Lebl

Auto-generated profile, based on publicly available information

Jan Lebl

Department of Paediatrics, 2nd Faculty of Medicine, Charles University In Prague and Motol University Hospital, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EPE. R. Pearson
E. R. Pearson
SPS. Pruhova
S. Pruhova
CTC. J. Tack
C. J. Tack
AJA. Johansen
A. Johansen
HCH. A. J. Castleden
H. A. J. Castleden
AHA. T. Hattersley
A. T. Hattersley

17 June 2010 in Sexual Development
Verified
Journal Article
Closed access
JPJ. Pleskacova
J. Pleskacova
RHR. Hersmus
R. Hersmus
JOJ.W. Oosterhuis
J.W. Oosterhuis
BSB.A. Setyawati
B.A. Setyawati
SFS.M. Faradz
S.M. Faradz
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
Certain patients with disorders of sex development (DSD), who bear Y chromosome material in their karyotype, are at increased risk for the development of type II germ cell tumors (GCT), which arise from early fetal germ cells. DSD gonads frequently harbor immature germ cells which express early fetal germ cell markers. Some of them (e.g. OCT3/4 and NANOG) seem to be of pathogenetic relevance in GCT development providing cells with the ability of pluripotency, proliferation and apoptosis suppression. Also TSPY (testis-specific protein Y-encoded), the main candidate for the so-called gonadoblastoma locus on Y chromosome, is overexpressed in germ cells of DSD patients and possibly contributes to their survival and proliferation. Nowadays, the use of immunohistochemical methods is highly relevant in identifying DSD gonads at risk. The risk for GCT development varies. While the prevalence of GCT is 15% in patients with partial androgen insensitivity, it may reach more than 30% in patients with gonadal dysgenesis. Patients with complete androgen insensitivity and ovotesticular DSD develop malignancies in 0.8% and 2.6% of cases, respectively. However, these data may be biased for various reasons. To better estimate the risk in individual groups of DSD, further investigations on large patient series are needed.

1 July 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MCMartine Cools
Martine Cools
JPJ. Pleskacova
J. Pleskacova
HSH. Stoop
H. Stoop
PHP. Hoebeke
P. Hoebeke
ELE. Van Laecke
E. Van Laecke
OGon behalf of the Mosaicism Collaborative Group
on behalf of the Mosaicism Collaborative Group
Context: Gonadectomy is avoided whenever possible in boys with 45,X/46,XY. However, no clinical markers are currently available to guide clinicians in predicting gonadal tumor risk or hormone production.Objective: The objective of the study was to test the hypothesis that gonadal histology and risk for development of a malignant germ cell tumor are reflected by the clinical presentation of a 45,X/46,XY individual.Design: The design of the study was the correlation of clinical data [external masculinization score (EMS), pubertal outcome] with pathology data (gonadal phenotype, tumor risk).Setting: This was a multicenter study involving two multidisciplinary disorder of sex development teams.Patients: Patients included genetically proven 45,X/46,XY (and variants) cases, of whom at least one gonadal biopsy or gonadectomy specimen was available, together with clinical details.Interventions: Patients (n = 48) were divided into three groups, based on the EMS. Gonadal histology and tumor risk were assessed on paraffin-embedded samples (n = 87) by morphology and immunohistochemistry on the basis of established criteria.Main Outcome Measures: Gonadal differentiation and tumor risk in the three clinical groups were measured. Clinical outcome in patients with at least one preserved gonad was also measured.Results: Tumor risk in the three groups was significantly related to the gonadal differentiation pattern (P < 0.001). In boys, hormone production was sufficient and was not predicted by the EMS.Conclusions: The EMS reflects gonadal differentiation and tumor risk in patients with 45,X/46,XY. In boys, testosterone production is often sufficient, but strict follow-up is warranted because of malignancy risk, which appears inversely related to EMS. In girls, tumor risk is limited but gonads are not functional, making gonadectomy the most reasonable option.

21 November 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AGAlexandra Gkourogianni
Alexandra Gkourogianni
MAMelissa Andrew
Melissa Andrew
LTLeah Tyzinski
Leah Tyzinski
MCMelissa Crocker
Melissa Crocker
JDJessica Douglas
Jessica Douglas
ADAndrew Dauber
Andrew Dauber
Context: Heterozygous mutations in the aggrecan gene (ACAN) cause autosomal dominant short stature with accelerated skeletal maturation. Objective: We sought to characterize the phenotypic spectrum and response to growth-promoting therapies. Patients and Methods: One hundred three individuals (57 females, 46 males) from 20 families with autosomal dominant short stature and heterozygous ACAN mutations were identified and confirmed using whole-exome sequencing, targeted next-generation sequencing, and/or Sanger sequencing. Clinical information was collected from the medical records. Results: Identified ACAN variants showed perfect cosegregation with phenotype. Adult individuals had mildly disproportionate short stature [median height, −2.8 standard deviation score (SDS); range, −5.9 to −0.9] and a history of early growth cessation. The condition was frequently associated with early-onset osteoarthritis (12 families) and intervertebral disc disease (9 families). No apparent genotype–phenotype correlation was found between the type of ACAN mutation and the presence of joint complaints. Childhood height was less affected (median height, −2.0 SDS; range, −4.2 to −0.6). Most children with ACAN mutations had advanced bone age (bone age − chronologic age; median, +1.3 years; range, +0.0 to +3.7 years). Nineteen individuals had received growth hormone therapy with some evidence of increased growth velocity. Conclusions: Heterozygous ACAN mutations result in a phenotypic spectrum ranging from mild and proportionate short stature to a mild skeletal dysplasia with disproportionate short stature and brachydactyly. Many affected individuals developed early-onset osteoarthritis and degenerative disc disease, suggesting dysfunction of the articular cartilage and intervertebral disc cartilage. Additional studies are needed to determine the optimal treatment strategy for these patients.

10 December 2013 in Diabetologia
Verified
Journal Article
Closed access
PDF file
JSJuraj Stanik
Juraj Stanik
PDPetra Dusatkova
Petra Dusatkova
OCOndrej Cinek
Ondrej Cinek
LVLucia Valentinova
Lucia Valentinova
MHMiroslava Huckova
Miroslava Huckova
SPStepanka Pruhova
Stepanka Pruhova

1 May 2007 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ETEva Al Taji
Eva Al Taji
HBHeike Biebermann
Heike Biebermann
ZLZdeňkA LímAnová
ZdeňkA LímAnová
OHOlga HníkOvá
Olga HníkOvá
JZJaroslav Zikmund
Jaroslav Zikmund
HKHeiko Krude
Heiko Krude
Objective: Mutations in NKX2.1, NKX2.5, FOXE1 and PAX8 genes, encoding for transcription factors involved in the development of the thyroid gland, have been identified in a minority of patients with syndromic and non-syndromic congenital hypothyroidism (CH). Design: In a phenotype-selected cohort of 170 Czech paediatric and adolescent patients with non-goitre CH, including thyroid dysgenesis, or non-goitre early-onset hypothyroidism, PAX8, NKX2.1, NKX2.5, FOXE1 and HHEX genes were analysed for mutations. Methods: NKX2.1, NKX2.5, FOXE1 and HHEX genes were directly sequenced in patients with syndromic CH. PAX8 mutational screening was performed in all 170 patients by single-stranded conformation polymorphism, followed by direct sequencing of samples with abnormal findings. The R52P PAX8 mutation was functionally characterized by DNA binding studies. Results: We identified a novel PAX8 mutation R52P, dominantly inherited in a three-generation pedigree and leading to non-congenital, early-onset, non-goitre, non-autoimmune hypothyroidism with gradual postnatal regression of the thyroid size and function. The R52P PAX8 mutation results in the substitution of a highly conserved residue of the DNA-binding domain with a loss-of-function effect. Conclusions: The very low frequency of genetic defects in a population-based cohort of children affected by non-goitre congenital and early-onset hypothyroidism, even in a phenotype-focussed screening study, suggests the pathogenetic role of either non-classic genetic mechanisms or the involvement of genes unknown so far. Identification of a novel PAX8 mutation in a particular variant of non-congenital early-onset hypothyroidism indicates a key function of PAX8 in the postnatal growth and functional maintenance of the thyroid gland.